Prevalence of metabolic syndrome higher in patients with psoriasis
Patients with psoriasis are at an increased risk for metabolic syndrome (MS), which is why clinicians should consider screening these individuals for metabolic risk factors, according to a recent study.
A systematic review and meta-analysis of observational studies on psoriasis and MS in adults was conducted to determine the association between the two. Researchers accessed Medline, Scopus, SciELO, Google Scholar, Science Direct and Lilacs from inception to January 2016.
A random effects model meta-analysis was performed for those studies that report adjusted odds ratios (ORs) with 95 percent CIs. The subgroup analysis was related to geographic location, diagnosis criteria and risk of bias.
A total of 14 papers including 25,042 patients with psoriasis met the inclusion criteria. Overall, 31.4 percent of participants had MS (OR, 1.42; 1.28 to 1.65). Middle Eastern studies (in Israel, Turkey and Lebanon) reported a higher risk for MS (OR, 1.76; 0.86 to 2.67) compared with European studies (in Germany, Italy, UK, Norway and Denmark; OR, 1.40; 1.25 to 1.55).
These findings supported the study by Armstrong and colleagues in 2013. According to their systematic review and meta-analysis of 12 observational studies, patients with psoriasis have higher prevalence of MS than the general population. Furthermore, those with more severe psoriasis are more likely to have MS than those with milder psoriasis. [J Am Acad Dermatol 2013;68:654-62]
The current study is limited by the small number of adjusted studies and the inconsistency between publications, according to researchers.